看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
* R. {- i' f/ N* [2 _# m
9 R- L/ D k% d. G9 P5 Y
% R" `3 y; W" @Currently available feasibility data for possible combination strategies.
) A# q! ?+ q) D" q( Y; B————————————————————————————————7 R# z7 y9 H0 w8 _& m
Combination Feasibility according to preliminary data 3 |9 _+ Z- z( g; Q% _# C% d) O. C+ {) P" Y
——————————————————————————————————
% O$ D) M0 F1 D& h0 `4 `7 o& ]Bevacizumab + sorafenib Yes, reduced dose
+ |+ ^) I8 @3 YBevacizumab + sunitinib† No
+ l3 B2 \& I) Y; b- n5 lBevacizumab + temsirolimus Yes
; ^! H& Q& G3 S7 b xBevacizumab + everolimus Yes
+ P1 p. Q" z) F7 q2 R; u: C9 v @Sorafenib + sunitinib ?
2 d- I& \7 x7 b1 ISorafenib + temsirolimus Yes, reduced dose
( r/ J) y9 b6 C% JSorafenib + everolimus Yes, reduced dose / `( b2 S. S- r) O% ^6 G1 i/ a. a
Sunitinib + temsirolimus† No # D7 k0 f" Y! _! k5 ]2 m7 S: \
Sunitinib + everolimus ? % k, w: g% [) C j J
Temsirolimus + everolimus ?
+ m. @- T% e9 _& J2 b————————————————————
. k. P1 \9 f& p$ f†Led to US FDA warning.+ m- V8 X/ V3 Z* v5 J
?: As yet unattempted combination.5 T' s0 k8 y' R2 k! a) B5 c I8 N
|